Since the beginning of this year, many pharmaceutical companies have been fined for environmental protection problems!

【Pharmaceutical Network Industry Dynamics】Under the background of the gradual introduction of policies such as domestic volume procurement, carbon neutrality, green economy, and national green API base, environmental protection issues have become the sword
of Damocles hanging high above the heads of enterprises.

It is understood that many enterprises have been fined
this year for environmental protection issues.

Among them, the amount of fines of more than 200,000 yuan is not a minority
.

For example, the Banlan root granules (product batch number 20210312) produced and sold by Wuhan Beishen Pharmaceutical Co.
, Ltd.
were determined by the Hubei Provincial Drug Administration to be inconsistent with the drug standards, and were ordered by the Hubei Provincial Drug Administration to correct the above illegal acts, and confiscated the 3919 packages of Banlangen granules recalled by the company and 7 packages of samples, a total of 3926 packages; The company was fined 3 times the value of the plate blue root granules illegally produced and sold by the company, that is, RMB 300,000
.

On January 29, 2022, Xinhua Pharmaceutical was fined 121,000 yuan
by the Zibo Municipal Bureau of Ecology and Environment for violating Article 18 of the Regulations on the Administration of Pollution Discharge Permits because the sewage outlet was not included in the management of the sewage permit, violating article 18 of the Regulations on the Administration of Pollution Discharge Permits.

On February 9, 2022, Xinhua Pharmaceutical was fined 132,000 yuan by the Zibo Municipal Bureau of Ecology and Environment, and fined a total of 253,800 yuan for two environmental protection issues because it violated Article 18 of the Regulations on the Administration of Pollution Discharge Permits
because the pollutant discharge methods and discharge destinations did not match the discharge permits.

In addition, Guangdong Yishu Pharmaceutical Co.
, Ltd.
, a subsidiary of Zhongsheng Pharmaceutical, was fined 250,000 yuan
by the relevant departments for the total phosphorus discharge concentration of the samples collected at the total discharge port of the wastewater was 6.
18mg/l, exceeding the standard by 12.
36 times, which violated the relevant provisions of the Pollution Prevention and Control Law.

In May, Nanjing Jianyou Pharmaceutical Co.
, Ltd.
was also fined 300,000 yuan by the Ecological Environment and Water Affairs Bureau of the Nanjing Jiangbei New Area Management Committee for "exceeding the standard" such as methanol emission concentration in the workshop.
On the whole, analysts believe that with the continuous attention of the pharmaceutical industry to green development, pharmaceutical companies will face the problem of how to grasp the trend of the industry and explore the realization
of high-quality sustainable development.

It is reported that in order to cope with the current situation of the industry, which is becoming stricter environmental protection, in fact, many enterprises in the pharmaceutical industry have begun to respond positively and implement the decision-making and deployment
of green transformation and development.

For example, Northeast Pharmaceutical has been actively pursuing the road of green, intelligent and sustainable development, and constantly improving environmental protection hardware supporting facilities
by introducing new processes and technologies for environmental protection.

It is reported that it has taken advantage of the overall relocation opportunity to invest more than 1 billion yuan in the construction of environmental protection projects, and the application of a number of environmental protection technologies and the construction of environmental protection devices are at the forefront
of the industry.

Since 1995, pharmaceutical companies have invested more than 400 million yuan
in the construction of sewage treatment plants alone.

Up to now, the pharmaceutical company has invested more than 1.
6 billion yuan in environmental protection infrastructure, of which the environmental protection operating expenses in 2019 reached 240 million yuan
.

In general, pharmaceutical companies are related to life and health, and they need to pay more attention to environmental protection and safety production
.

The industry believes that in the context of the continuous change of the industry pattern and the tightening of supervision, pharmaceutical companies that have laid out environmental protection strategies in advance and realized green production can be less affected by policies and create more stable profits
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.